2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1466

Altered Count of NK Cells and Non-Classical Monocyte Subpopulation in the Pre-Clinical Phase of Rheumatoid Arthritis
Abstract Number: 72

Altered Serologic Responses to Epstein Barr Virus Precede Clinical Disease Development in Rheumatoid Arthritis
Abstract Number: 710

An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival
Abstract Number: 576

An Analysis of Early Introduction of Adalimumab and Subsequent Bio-Free Condition in the Patients with Rheumatoid Arthritis
Abstract Number: 1553

An Analysis of Real-World Data on the Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis
Abstract Number: 1372

An Analysis of the Quality and Readability of Online Osteoarthritis Information with Historical Comparison
Abstract Number: 2231

An Ancestral-Specific Interaction of TRIM46 with a Past-History of Smoking May Influence Gout Risk
Abstract Number: 972

An Anti-CD28 Domain Antibody, Lulizumab, in Systemic Lupus Erythematosus: Results of a Phase II Study
Abstract Number: 1858

An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis
Abstract Number: 2184

An Economic Evaluation on the Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4d Activation Products in a Multivariate Assay Panel (MAP)
Abstract Number: 1757

An Economic Systematic Literature Review of Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 2857

An Electronic Audit, Reporting, and Data Correction System Improves the Quantity and Quality of Observational Data Collected for US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
Abstract Number: 1028

An Entheseal Innate Immune Cell Biological Basis for Differential Efficacy of PDE4 and IL-23 Pathway Blockade between Psoriatic Disease and Rheumatoid Arthritis
Abstract Number: 2919

An Epidemic: Severe Lung Disease in Patients with Systemic Juvenile Idiopathic Arthritis, Risk Factors and Predictors
Abstract Number: 1250

An Evaluation of Utilization Patterns and Appropriateness of Laboratory Tests Among New Referrals to Rheumatologists: Choosing Unwisely!

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].